Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Quantum Biopharma Ltd. QNTM

5 fiscal years on record · USD · FY2022 reported · SEC filings only
$-23.6M
$-28.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company has also licensed unbuzzd™, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption, to Unbuzzd and Celly U.S., and is entitled to a royalty on the revenue generated by Unbuzzd and Celly U.S. from sales of products created using the technology rights granted under the Unbuzzd IP License Agreement. Finally, the Company has expanded its corporate treasury management function to include investments in cryptocurrencies. unbuzzd™ is a consumer recreational beverage product that will be sold via retail distribution.

Written from the business description in Quantum BioPharma Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2022 · full 5-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2022 · ROE -55.8%
-50%-100%
201820202022
Three returns, three denominators.

Each USD of equity lost 56 cents this year.

Cash & shareholders

·
returned in FY2022 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -28.4
-10M-20M
201820202022

Total assetsUSD 38.4M
EquityUSD 30.5M
CashUSD 17.0M
Current ratio2.28×

Equity funds 80% of total assets.

The 5-year record

5 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
QNTM, 5-year financial record
Metric 20222021202020192018
Revenue CAD B◌◌◌0.0◌
Operating income $B−0.0−0.0−0.0−0.0◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0
Income tax $B◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0◌
Free cash flow $B−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.69−0.97−2.36◌◌
Dividend / sh $◌◌◌◌◌
Payout % — not applicable: no dividend—————
ROE %−55.8−78.0−87.6−104.8−59.2

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures · 1 divergence in 28 reconciliationsAUDITED

Reconciled in 3 of the 5 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 22 checks were skipped: the balance sheet is not tagged before 2018. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A6
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image